Prostaglandin e2 modulation and uses thereof
AssigneeUniversite Laval
InventorsJack PUYMIRAT, Daniel Beaulieu, Pierre Chapdelaine
Life of this patent
Estimating the term…
Abstract
Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).
Claims12
A method for determining whether a test compound is useful for preventing and/or treating cDM1, said method comprising determining the level and/or activity of (i) PGE2, (ii) a mediator involved in PGE2 biosynthesis, or (iii) both (i) and (ii), in a cell comprising (i) PGE2, (ii) a mediator involved in PGE2 biosynthesis, or (iii) both (i) and (ii), and/or PGE2 biosynthetic activity;
- wherein a decrease in the level and/or activity in the presence relative to the absence of said test compound is indicative that said test compound is useful for preventing and/or treating cDM1.
A method for determining whether a test compound is useful for preventing and/or treating cDM1, said method comprising:
- (a) contacting a biological sample from a subject at risk of or suffering from cDM1 with said test compound;
- and
- (b) determining the level and/or activity of (i) PGE2, (ii) a mediator involved in PGE2 biosynthesis, or (iii) both (i) and (ii);
- wherein a decrease in the level and/or activity in the presence relative to in the absence of said test compound is indicative that said test compound is useful for preventing and/or treating cDM1.
A method for determining whether a test compound is useful for preventing and/or treating cDM1, said method comprising assaying the level and/or activity of (i) PGE2, (ii) a mediator involved in PGE2 biosynthesis, or (iii) both (i) and (ii), in the presence versus in the absence of said test compound, wherein a decrease in the level and/or activity in the presence relative to the absence of said test compound is indicative that said test compound is useful for preventing and/or treating cDM1.
Dependencies are inferred from the claim text.